Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate

糠酸莫米松 丙酸氟替卡松 交叉研究 医学 药代动力学 氟替卡松 皮质类固醇 安慰剂 最大值 药理学 麻醉 鼻喷雾剂 内科学 鼻腔给药 替代医学 病理
作者
Peter T. Daley‐Yates,Amanda Deans,Rashmi S. Mehta,Ana R. Sousa
出处
期刊:Pulmonary Pharmacology & Therapeutics [Elsevier BV]
卷期号:77: 102171-102171 被引量:7
标识
DOI:10.1016/j.pupt.2022.102171
摘要

To investigate the pharmacokinetics and effects on the hypothalamic-pituitary-adrenal (HPA) axis of mometasone furoate (MF), fluticasone propionate (FP) and fluticasone furoate (FF). Study 1: Fourteen healthy participants received inhaled and intravenous MF (inhaled dose via Twisthaler) and FP (inhaled dose via Diskus), both given at 400 μg, using a randomised, single-dose, four-way crossover design. Study 2: Twenty-seven participants with mild to moderate asthma, who discontinued their corticosteroid medication for 5 days to obtain a baseline 24 h serum cortisol, received inhaled MF Twisthaler and FP Diskus, both given at 400 μg twice daily (BID), using a randomised, 14-day repeat dose, two-way crossover design. Study 3: Forty-four healthy participants were randomised to a double-blind, placebo-controlled, five-period crossover study where the following treatments were administered via the inhaled route for 7 days: FP Diskus (250, 500, 1000 μg BID), FF Diskus (100, 200, 400, 800, 1600 μg once daily [QD]) or placebo Diskus. In each study, 24-h serial blood samples were collected and assayed to assess concentrations of MF, 6β-hydroxy mometasone, mometasone, FP, FF and cortisol. Pharmacokinetic and serum cortisol parameters were estimated as geometric means and 95% confidence intervals (CI). Study 1: For intravenous MF and FP, respectively: absolute bioavailability was 11.4% (95% CI: 7.5, 17.6) and 7.8% (6.3, 9.6); plasma clearance was 47 L/h (41, 52) and 60 L/h (52, 69); half-life was 7.4 h (6.9, 8.0) and 7.2 h (6.5, 8.0); and volume of distribution was 499 L (439, 567) and 623 L (557, 698). Inhalation of single dose MF or FP did not significantly affect serum cortisol (<10% reduction from baseline), whereas intravenous administration of MF or FP each changed serum cortisol by approximately −50% from baseline. Study 2: For MF and FP, respectively: area under the curve up to the last measurable concentration on Day 1 was 421 pg h/mL (270, 659) and 248 pg h/mL (154, 400), and on Day 14 was 1092 pg h/mL (939, 1269) and 591 pg h/mL (501, 696); absolute bioavailability was 12.8% (11.2, 14.2) and 8.9% (7.7, 10.2). On Day 14, 24-h serum cortisol change from baseline was −35% (−44%, −26%) and −18% (−28%, −5%) for MF and FP, respectively; the reduction was significantly greater for MF than FP (ratio for geometric adjusted mean serum cortisol concentration: 1.28 [1.04, 1.56]). Low plasma concentrations of 6β-hydroxy mometasone were detected after intravenous dosing (Study 1) and after multiple inhaled dosing (Study 2); mometasone was not detected in any samples. Study 3: Inhaled FP and FF had similar systemic bioavailability estimates (12.0% [11.0, 13.2] and 15.0% [12.0, 17.3], respectively), but a differential effect on the HPA axis which was in agreement with the known 1.7-fold higher glucocorticoid receptor-binding affinity of FF versus FP. However, for FP 250 μg BID and FF 100, 200 and 400 μg QD, reduction in serum cortisol was not significantly different from placebo. For higher doses, FP 500 and 1000 μg BID, and FF 800 and 1600 μg QD, changes in serum cortisol concentration relative to placebo were −30%, −70%, −41% and −90%, respectively. Repeat inhaled dosing of FP 1000 μg/day (within the therapeutic dose range) resulted in comparable cortisol suppression to MF in the therapeutic range (30% reduction); whereas for FF this occurred at more than 3-fold above the therapeutic dose range (644 μg/day). Single inhaled and intravenous doses of MF and FP (400 μg) resulted in similar bioavailability and reductions in serum cortisol. Repeat dosing of inhaled MF and FP in the therapeutic range (800 μg/day) resulted in greater systemic exposure for MF, and a 35% reduction in serum cortisol that was 2-fold greater than for FP. The higher glucocorticoid receptor-binding affinity and bioavailability, lower clearance and the presence of active metabolites may contribute to the greater systemic exposure and effect on cortisol for MF. Repeat dosing of inhaled FP and FF resulted in similar systemic bioavailability but differed in terms of the dose required for comparable cortisol suppression to MF in the therapeutic range. Unlike FP and FF, MF has active metabolites that may contribute to its systemic effects, while device/formulation performance differences also exist between MF-containing products.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
eason楽发布了新的文献求助10
刚刚
蓝月半发布了新的文献求助10
刚刚
LUO发布了新的文献求助10
1秒前
1秒前
wyt完成签到,获得积分10
2秒前
2秒前
VanillaTwilight完成签到,获得积分10
2秒前
DW的应助被爱听歌安阳采纳,获得10
2秒前
2秒前
2秒前
iDong完成签到,获得积分10
2秒前
2秒前
dra7vu完成签到,获得积分10
2秒前
wuhhoo发布了新的文献求助10
3秒前
3秒前
从容的丹南完成签到 ,获得积分10
3秒前
3秒前
lykkk发布了新的文献求助10
3秒前
May发布了新的文献求助10
4秒前
Xin完成签到,获得积分10
4秒前
Akim的应助被leo采纳,获得10
4秒前
4秒前
今晚雨很大完成签到,获得积分10
4秒前
追寻澜发布了新的文献求助10
5秒前
5秒前
小王完成签到 ,获得积分10
5秒前
5秒前
小蘑菇的应助被xx2026采纳,获得10
6秒前
张伟的应助被完美平文采纳,获得10
6秒前
很好完成签到 ,获得积分10
7秒前
7秒前
和谐的蜡烛完成签到,获得积分10
7秒前
YaoHui发布了新的文献求助10
7秒前
尹相汛的应助被iDong采纳,获得10
7秒前
7秒前
Sara完成签到,获得积分10
7秒前
7秒前
Lucas的应助被sunny采纳,获得10
7秒前
8秒前
sun发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162755
求助须知:如何正确求助?哪些是违规求助? 9557016
关于积分的说明 21737907
捐赠科研通 7753093
什么是DOI,文献DOI怎么找? 3427901
关于科研通互助平台的介绍 2552719
邀请新用户注册赠送积分活动 2472528